Josiane S Neves1, Amy L Radke, Peter F Weller. 1. Division of Allergy and Inflammation, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Abstract
BACKGROUND: Cysteinyl leukotrienes (cysLTs) are recognized to act via receptors (cysLTRs) expressed on cell surface plasma membranes. Agents that block cysLT(1) receptor (cysLT(1)R) are therapeutics for allergic disorders. Eosinophils contain multiple preformed proteins stored within their intracellular granules. Cell-free eosinophil granules are present extracellularly as intact membrane-bound organelles in sites associated with eosinophil infiltration, including asthma, rhinitis, and urticaria, but have unknown functional capabilities. OBJECTIVE: We evaluated the expression of cysLTRs on eosinophil granule membranes and their functional roles in eliciting protein secretion from within eosinophil granules. METHODS: We studied secretory responses of human eosinophil granules isolated by subcellular fractionation. Granules were stimulated with cysLTs, and eosinophil cationic protein and cytokines were measured in the supernatants. Receptor expression on granule membranes and eosinophils was evaluated by flow cytometry and Western blot. RESULTS: We report that receptors for cysLTs, cysLT(1)R, cysLT(2) receptor, and the purinergic P2Y12 receptor, are expressed on eosinophil granule membranes. Leukotriene (LT) C(4) and extracellularly generated LTD(4) and LTE(4) stimulated isolated eosinophil granules to secrete eosinophil cationic protein. MRS 2395, a P2Y12 receptor antagonist, inhibited cysLT-induced eosinophil cationic protein release. Montelukast, likely not solely as an inhibitor of cysLT(1)R, inhibited eosinophil cationic protein release elicited by LTC(4) and LTD(4) as well as by LTE(4). CONCLUSION: These studies identify previously unrecognized sites of localization, the membranes of intracellular eosinophil granule organelles, and function for cysLT-responsive receptors that mediate cysteinyl leukotriene-stimulated secretion from within eosinophil granules, including those present extracellularly. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
BACKGROUND:Cysteinyl leukotrienes (cysLTs) are recognized to act via receptors (cysLTRs) expressed on cell surface plasma membranes. Agents that block cysLT(1) receptor (cysLT(1)R) are therapeutics for allergic disorders. Eosinophils contain multiple preformed proteins stored within their intracellular granules. Cell-free eosinophil granules are present extracellularly as intact membrane-bound organelles in sites associated with eosinophil infiltration, including asthma, rhinitis, and urticaria, but have unknown functional capabilities. OBJECTIVE: We evaluated the expression of cysLTRs on eosinophil granule membranes and their functional roles in eliciting protein secretion from within eosinophil granules. METHODS: We studied secretory responses of human eosinophil granules isolated by subcellular fractionation. Granules were stimulated with cysLTs, and eosinophil cationic protein and cytokines were measured in the supernatants. Receptor expression on granule membranes and eosinophils was evaluated by flow cytometry and Western blot. RESULTS: We report that receptors for cysLTs, cysLT(1)R, cysLT(2) receptor, and the purinergic P2Y12 receptor, are expressed on eosinophil granule membranes. Leukotriene (LT) C(4) and extracellularly generated LTD(4) and LTE(4) stimulated isolated eosinophil granules to secrete eosinophil cationic protein. MRS 2395, a P2Y12 receptor antagonist, inhibited cysLT-induced eosinophil cationic protein release. Montelukast, likely not solely as an inhibitor of cysLT(1)R, inhibited eosinophil cationic protein release elicited by LTC(4) and LTD(4) as well as by LTE(4). CONCLUSION: These studies identify previously unrecognized sites of localization, the membranes of intracellular eosinophil granule organelles, and function for cysLT-responsive receptors that mediate cysteinyl leukotriene-stimulated secretion from within eosinophil granules, including those present extracellularly. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: Davide Ferrari; Andrea la Sala; Elisabeth Panther; Johannes Norgauer; Francesco Di Virgilio; Marco Idzko Journal: J Leukoc Biol Date: 2005-10-21 Impact factor: 4.962
Authors: J F Cheng; N L Ott; E A Peterson; T J George; M J Hukee; G J Gleich; K M Leiferman Journal: J Allergy Clin Immunol Date: 1997-05 Impact factor: 10.793
Authors: K R Lynch; G P O'Neill; Q Liu; D S Im; N Sawyer; K M Metters; N Coulombe; M Abramovitz; D J Figueroa; Z Zeng; B M Connolly; C Bai; C P Austin; A Chateauneuf; R Stocco; G M Greig; S Kargman; S B Hooks; E Hosfield; D L Williams; A W Ford-Hutchinson; C T Caskey; J F Evans Journal: Nature Date: 1999-06-24 Impact factor: 49.962
Authors: Liaman Mamedova; Valérie Capra; Maria Rosa Accomazzo; Zhan-Guo Gao; Silvia Ferrario; Marta Fumagalli; Maria P Abbracchio; G Enrico Rovati; Kenneth A Jacobson Journal: Biochem Pharmacol Date: 2005-11-08 Impact factor: 5.858
Authors: Christian Kamp Nielsen; Joan I A Campbell; John F Ohd; Matthias Mörgelin; Kristian Riesbeck; Göran Landberg; Anita Sjölander Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701
Authors: John W Steinke; Julie Negri; Spencer C Payne; Larry Borish Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2014-03-26 Impact factor: 4.006
Authors: Revital Shamri; Rossana C N Melo; Kristen M Young; Maytal Bivas-Benita; Jason J Xenakis; Lisa A Spencer; Peter F Weller Journal: FASEB J Date: 2012-01-31 Impact factor: 5.191
Authors: Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405